Kyverna Therapeutics, Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Sean E Harper. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Sean E Harper has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:KYTX / Kyverna Therapeutics, Inc. 10% Owner 735,984
US:SLRN / Acelyrin, Inc. 10% Owner 9,790,729
US:AMGN / Amgen Inc. EVP, Research & Development 56,082
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Sean E Harper. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases KYTX / Kyverna Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in KYTX / Kyverna Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KYTX / Kyverna Therapeutics, Inc. Insider Trades
Insider Sales KYTX / Kyverna Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in KYTX / Kyverna Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KYTX / Kyverna Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Sean E Harper as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-02-14 2024-02-12 4 KYTX Kyverna Therapeutics, Inc.
Common Stock
C - Conversion 735,984 735,984
2024-02-14 2024-02-12 4 KYTX Kyverna Therapeutics, Inc.
Common Stock
C - Conversion 3,787,940 3,787,940
2023-05-11 2023-05-09 4 SLRN ACELYRIN, Inc.
Common Stock
P - Purchase 1,250,000 9,790,729 14.64 18.00 22,500,000 176,233,122
2023-05-11 2023-05-09 4 SLRN ACELYRIN, Inc.
Common Stock
C - Conversion 8,540,729 8,540,729
2018-07-16 2018-07-16 4 AMGN AMGEN INC
Common Stock
S - Sale X -1,525 56,082 -2.65 195.71 -298,458 10,975,808
2018-06-12 2018-06-12 4 AMGN AMGEN INC
Common Stock
S - Sale X -1,525 57,510 -2.58 184.27 -281,012 10,597,368
2018-05-15 2018-05-14 4 AMGN AMGEN INC
Common Stock
S - Sale X -1,525 59,035 -2.52 174.10 -265,502 10,277,994
2018-05-07 2018-05-03 4 AMGN AMGEN INC
Common Stock
F - Taxes -736 60,560 -1.20 169.43 -124,700 10,260,681
2018-05-01 2018-04-27 4 AMGN AMGEN INC
Nqso (Right to Buy)
A - Award 34,702 34,702
2018-05-01 2018-04-27 4 AMGN AMGEN INC
Common Stock
A - Award 4,508 61,296 7.94
2018-04-16 2018-04-12 4 AMGN AMGEN INC
Common Stock
S - Sale X -1,525 56,788 -2.62 172.68 -263,337 9,806,152
2018-03-27 2018-03-23 4 AMGN AMGEN INC
Common Stock
F - Taxes -7,549 58,313 -11.46 176.08 -1,329,228 10,267,753
2018-03-19 2018-03-16 4 AMGN AMGEN INC
Common Stock
S - Sale X -1,525 65,682 -2.27 189.75 -289,369 12,463,160
2018-03-09 2018-03-07 4 AMGN AMGEN INC
Common Stock
A - Award 15,118 67,207 29.02
2018-02-15 2018-02-14 4 AMGN AMGEN INC
Common Stock
S - Sale X -1,525 52,089 -2.84 174.18 -265,624 9,072,862
2018-02-01 2018-01-31 4 AMGN AMGEN INC
Common Stock
F - Taxes -606 53,614 -1.12 191.27 -115,910 10,254,750
2018-02-01 2018-01-30 4 AMGN AMGEN INC
Common Stock
F - Taxes -453 54,200 -0.83 198.00 -89,694 10,731,600
2018-01-17 2018-01-16 4 AMGN AMGEN INC
Common Stock
S - Sale X -1,525 54,673 -2.71 185.62 -283,070 10,148,402
2017-12-12 2017-12-12 4 AMGN AMGEN INC
Common Stock
S - Sale X -1,525 56,106 -2.65 176.83 -269,666 9,921,224
2017-11-14 2017-11-13 4 AMGN AMGEN INC
Common Stock
S - Sale X -1,525 57,631 -2.58 171.58 -261,660 9,888,327
2017-10-10 2017-10-09 4 AMGN AMGEN INC
Common Stock
S - Sale X -1,525 59,156 -2.51 185.95 -283,574 11,000,058
2017-05-03 2017-05-01 4 AMGN AMGEN INC
Nqso (Right to Buy)
A - Award 40,305 40,305
2017-05-03 2017-05-01 4 AMGN AMGEN INC
Common Stock
A - Award 4,551 60,496 8.13
2017-03-28 2017-03-24 4 AMGN AMGEN INC
Common Stock
F - Taxes -12,128 55,945 -17.82 166.04 -2,013,733 9,289,108
2017-03-09 2017-03-07 4 AMGN AMGEN INC
Common Stock
A - Award 23,092 67,866 51.57
2017-02-02 2017-01-31 4 AMGN AMGEN INC
Common Stock
F - Taxes -668 44,774 -1.47 154.43 -103,159 6,914,449
2017-01-31 2017-01-30 4 AMGN AMGEN INC
Common Stock
F - Taxes -513 45,442 -1.12 157.16 -80,623 7,141,665
2017-01-31 2017-01-28 4 AMGN AMGEN INC
Common Stock
F - Taxes -1,056 45,955 -2.25 157.16 -165,961 7,222,288
2016-05-05 2016-05-03 4 AMGN AMGEN INC
Nqso (Right to Buy)
A - Award 38,112 38,112
2016-05-05 2016-05-03 4 AMGN AMGEN INC
Common Stock
A - Award 4,477 46,725 10.60
2016-05-03 2016-04-29 4 AMGN AMGEN INC
Common Stock
S - Sale -21,875 42,248 -34.11 157.99 -3,456,134 6,674,960
2016-04-29 2016-04-27 4 AMGN AMGEN INC
Common Stock
F - Taxes -1,659 64,123 -2.52 162.85 -270,168 10,442,431
2016-03-29 2016-03-25 4 AMGN AMGEN INC
Common Stock
F - Taxes -23,785 65,782 -26.56 149.24 -3,549,673 9,817,306
2016-03-04 2016-03-02 4 AMGN AMGEN INC
Common Stock
A - Award 45,268 89,162 103.13
2016-02-01 2016-01-31 4 AMGN AMGEN INC
Common Stock
F - Taxes -651 43,894 -1.46 152.73 -99,427 6,703,931
2016-02-01 2016-01-28 4 AMGN AMGEN INC
Common Stock
F - Taxes -999 44,281 -2.21 150.47 -150,320 6,662,962
2015-04-28 2015-04-27 4 AMGN AMGEN INC
Common Stock
F - Taxes -1,575 45,280 -3.36 167.91 -264,458 7,602,965
2015-04-28 2015-04-25 4 AMGN AMGEN INC
Common Stock
F - Taxes -1,065 46,855 -2.22 167.91 -178,824 7,867,423
2015-04-23 2015-04-22 4 AMGN AMGEN INC
Common Stock
S - Sale -28,000 47,920 -36.88 171.58 -4,804,240 8,222,114
2015-03-31 2015-03-27 4 AMGN AMGEN INC
Common Stock
F - Taxes -28,624 75,920 -27.38 160.55 -4,595,583 12,188,956
2015-03-06 2015-03-04 4 AMGN AMGEN INC
Common Stock
A - Award 54,577 104,162 110.07
2015-02-03 2015-01-30 4 AMGN AMGEN INC
Common Stock
A - Award 3,940 49,585 8.63
2015-01-30 2015-01-28 4 AMGN AMGEN INC
Common Stock
F - Taxes -35 45,645 -0.08 158.89 -5,561 7,252,534
2015-01-30 2015-01-28 4 AMGN AMGEN INC
Common Stock
F - Taxes -928 45,680 -1.99 158.89 -147,450 7,258,095
2015-01-05 2014-12-31 4 AMGN AMGEN INC
Common Stock
F - Taxes -13,046 46,608 -21.87 160.63 -2,095,579 7,486,643
2014-08-07 2014-08-05 4 AMGN AMGEN INC
Common Stock
S - Sale -14,000 59,503 -19.05 127.29 -1,782,126 7,574,417
2014-04-29 2014-04-27 4 AMGN AMGEN INC
Common Stock
F - Taxes -56 73,407 -0.08 111.41 -6,239 8,178,274
2014-04-29 2014-04-27 4 AMGN AMGEN INC
Common Stock
F - Taxes -1,490 73,463 -1.99 111.41 -166,001 8,184,513
2014-04-29 2014-04-26 4 AMGN AMGEN INC
Common Stock
F - Taxes -601 74,953 -0.80 111.41 -66,957 8,350,514
2014-04-29 2014-04-25 4 AMGN AMGEN INC
Common Stock
F - Taxes -1,034 75,554 -1.35 113.72 -117,586 8,592,001
2014-03-18 2014-03-14 4 AMGN AMGEN INC
Common Stock
F - Taxes -7,683 76,588 -9.12 123.96 -952,385 9,493,848
2014-03-07 2014-03-05 4 AMGN AMGEN INC
Common Stock
A - Award 14,724 84,163 21.20
2014-02-04 2014-01-31 4 AMGN AMGEN INC
Common Stock
A - Award 5,044 69,439 7.83
2013-05-06 2013-05-02 4 AMGN AMGEN INC
Nqso (Right to Buy)
M - Exercise -8,000 0 -100.00
2013-05-06 2013-05-02 4 AMGN AMGEN INC
Common Stock
S - Sale -8,000 64,180 -11.08 106.32 -850,590 6,823,855
2013-05-06 2013-05-02 4 AMGN AMGEN INC
Common Stock
M - Exercise 8,000 72,180 12.46 50.44 403,520 3,640,759
2013-04-30 2013-04-28 4 AMGN AMGEN INC
Common Stock
F - Taxes -588 64,180 -0.91 108.38 -63,727 6,955,828
2013-04-30 2013-04-26 4 AMGN AMGEN INC
Common Stock
F - Taxes -601 64,768 -0.92 108.66 -65,305 7,037,691
2013-04-29 2013-04-25 4 AMGN AMGEN INC
Common Stock
F - Taxes -1,034 65,369 -1.56 104.93 -108,498 6,859,169
2013-03-19 2013-03-15 4 AMGN AMGEN INC
Common Stock
F - Taxes -6,918 66,403 -9.44 92.18 -637,701 6,121,029
2013-03-08 2013-03-06 4 AMGN AMGEN INC
Common Stock
A - Award 13,257 73,238 22.10
2013-01-30 2013-01-28 4 AMGN AMGEN INC
Common Stock
A - Award 7,477 59,981 14.24
2012-07-31 2012-07-27 4 AMGN AMGEN INC
Nqso (Right to Buy)
M - Exercise -14,400 0 -100.00
2012-07-31 2012-07-27 4 AMGN AMGEN INC
Nqso (Right to Buy)
M - Exercise -16,109 0 -100.00
2012-07-31 2012-07-27 4 AMGN AMGEN INC
Nqso (Right to Buy)
M - Exercise -8,000 16,000 -33.33
2012-07-31 2012-07-27 4 AMGN AMGEN INC
Iso (Right to Buy)
M - Exercise -1,391 0 -100.00
2012-07-31 2012-07-27 4 AMGN AMGEN INC
Common Stock
S - Sale -39,900 52,432 -43.21 82.33 -3,285,087 4,316,884
2012-07-31 2012-07-27 4 AMGN AMGEN INC
Common Stock
M - Exercise 14,400 84,332 20.59 69.78 1,004,832 5,884,687
2012-07-31 2012-07-27 4 AMGN AMGEN INC
Common Stock
M - Exercise 16,109 69,932 29.93 71.88 1,157,915 5,026,712
2012-07-31 2012-07-27 4 AMGN AMGEN INC
Common Stock
M - Exercise 8,000 61,823 14.86 58.43 467,440 3,612,318
2012-07-31 2012-07-27 4 AMGN AMGEN INC
Common Stock
M - Exercise 1,391 53,823 2.65 71.88 99,985 3,868,797
2012-05-03 2012-05-03 4 AMGN AMGEN INC
Nqso (Right to Buy)
M - Exercise -8,000 8,000 -50.00
2012-05-03 2012-05-03 4 AMGN AMGEN INC
Nqso (Right to Buy)
M - Exercise -6,000 0 -100.00
2012-05-03 2012-05-03 4 AMGN AMGEN INC
Common Stock
F - Taxes -6,758 52,387 -11.43 71.17 -480,967 3,728,383
2012-05-03 2012-05-03 4 AMGN AMGEN INC
Common Stock
F - Taxes -4,695 59,145 -7.35 71.17 -334,143 4,209,350
2012-05-03 2012-05-03 4 AMGN AMGEN INC
Common Stock
M - Exercise 8,000 63,840 14.33 50.44 403,520 3,220,090
2012-05-03 2012-05-03 4 AMGN AMGEN INC
Common Stock
M - Exercise 6,000 55,840 12.04 42.13 252,780 2,352,539
2012-05-01 2012-04-29 4 AMGN AMGEN INC
Common Stock
F - Taxes -2,545 49,840 -4.86 71.64 -182,324 3,570,538
2012-05-01 2012-04-28 4 AMGN AMGEN INC
Common Stock
F - Taxes -526 52,385 -0.99 71.64 -37,683 3,752,861
2012-05-01 2012-04-27 4 AMGN AMGEN INC
Common Stock
A - Award 8,654 52,911 19.55
2012-04-30 2012-04-26 4 AMGN AMGEN INC
Common Stock
F - Taxes -514 44,257 -1.15 70.19 -36,078 3,106,399
2012-03-20 2012-03-16 4 AMGN AMGEN INC
Common Stock
F - Taxes -1,519 44,771 -3.28 68.26 -103,687 3,056,068
2012-03-15 2012-03-14 4 AMGN AMGEN INC
Common Stock
A - Award 4,140 46,290 9.82
2012-02-16 3 AMGN AMGEN INC
Common Stock
42,150
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)